Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Integrating Immunotherapy into the MIUC Treatment Paradigm
May 15, 2025 | 3:30 PM ET
The standard treatment for muscle-invasive urothelial carcinoma (MIUC) has been radical surgery combined with cisplatin-based chemotherapy for eligible patients. However, over 50% of patients face metastatic progression after surgery. This non-CME webinar, presented by a urology expert, will discuss how patients with UC at high risk of recurrence after radical resection may benefit from adjuvant immunotherapy, emphasize the role of multidisciplinary communication in patient care, and review a subcutaneous immunotherapy option for the adjuvant treatment of UC.
Gautam Jayram, MD
Dr. Jayram is a urologist and Director of the Advanced Therapeutics Center at Urology Associates, PC, in Nashville, Tennessee. He attended Vanderbilt University School of Medicine and completed his urology residency at the University of Chicago Hospitals. He then spent two years in Baltimore, Maryland, where he completed a fellowship at Johns Hopkins’ Brady Urological Institute and served as a clinical instructor. Dr. Jayram has a busy urologic oncology practice in Nashville and performs a high volume of prostate, bladder, and kidney cancer procedures yearly. At the Advanced Therapeutics Center, he directs one of the busiest urologic cancer clinical trials programs in the country. He has served in several advisory roles and sits on multiple trial steering committees. He currently is very involved in improving oncology clinical pathways for community urology and sits on the Education Committee for the Large Urology Group Practice Association (LUGPA).